Trial Profile
Randomized maintenance therapy with Azacitidine (Vidaza) in older patients (≥ 60 years of age) with acute myeloid leukemia (AML) and refractory anemia with excess of blasts (RAEB, RAEB-t). A phase III study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Jan 2023
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary)
- Indications Acute myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms HOVON 97 AML
- 13 Jan 2023 According to European Clinical Trials Database registry, this trial has been completed in Belgium.
- 14 Dec 2021 Results from HOVON97 and QUAZAR AML-001, determining the relative safety profile and health care resource utilization with Oral-AZA vs SC AZA maintenance therapy in pts with AML in first remission after intensive chemotherapy, presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 17 Jun 2021 Results of a comparative analysis of relative efficacy of maintenance therapy with oral versus injectable azacitidine in patients with Acute-myeloid-leukaemia in first remission after chemotherapy performed by matching individual patients data from QUAZAR AML-001 study to summary level data from the HOVON97 and QoLESS studies presented at the 26th Congress of the European Haematology Association